RUNX2 Prompts Triple Negative Breast Cancer Drug Resistance through TGF-β Pathway Regulating Breast Cancer Stem Cells

Scientists took a multifaceted approach from in vitro and in vivo experiments to validate the relationship between RUNX2 and TGF-β and to search for their pathogenic mechanisms in chemoresistance.